Pirprofen-associated hepatic injury.
Four cases of hepatic injury attributed to the use of pirprofen (Rengasil) were reported to the Monitoring Centres for Adverse Reactions of Belgium, The Netherlands and the German Medical Association. One man and three women developed severe hepatic injury between 3 1/2 and 6 1/2 months after starting treatment with 400-1200 mg pirprofen daily. Histology showed acute hepatocellular damage, often with bridging necrosis. Two patients died. The other two patients made an incomplete recovery. It is possible that this severe type of hepatic injury is due to a metabolic idiosyncrasy to pirprofen, as this reaction seems to be rare and unpredictable but is not associated with immunoallergic signs.
D000328:Adult; D000368:Aged; D001168:Arthritis / Q000188:drug therapy; D005260:Female; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000293:injuries* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009336:Necrosis; D010003:Osteoarthritis / Q000188:drug therapy; D010666:Phenylpropionates / Q000009:adverse effects*; D011565:Psoriasis / Q000188:drug therapy; D013997:Time Factors
D010666:Phenylpropionates; C008924:pirprofen